A comparative study on efficacy of topical dorzolamide and topical nevanac in central serous retinopathy

Abstract

Introduction: Central serous chorioretinopathy (CSR) is mostly an idiopathic ocular disorder characterized by a serous detachment of the neurosensory retina at the macula, caused by active retinal pigment epithelial leakage. Nepafenac is a topical non-steroidal anti-inflammatory prodrug that acts by blocking prostaglandins' synthesis, thereby decreasing inflammation. Whereas carbonic anhydrase inhibitors like dorzolamide effectively manage subretinal and intraretinal fluid absorption through Retinal Pigment Epithelium (RPE), resulting in decreasing in CSR. Materials and Methods: A pilot study on four patients diagnosed with acute CSR was done in a medical college in Andhra Pradesh for a period of 2 months. Patient A, B, C and D are diagnosed as having a cute CSR relying upon Visual acuity, dilated fundus examination and OCT findings. Patient A and B were treated with Nepafenac eye drops thrice daily, and patient C and D with Dorzolamide eye drops twice daily. All patients were followed up on the 1st, 2nd, 3rd and 4th week. On each visit, vision, dilated fundoscopy, and OCT were performed. Results: All Patients were followed up from the day of presentation to the 30th day. Central Macular thickness and visual acuity recorded from 1st week till 4th week shows early resolution of submacular fluid in all the patients. It was noted that there was a rapid resolution of CSR in patient C and D treated with Dorzolamide compared to patient A and B treated with Nepafenac.